Lexaria Bioscience Corp. (LEXX)

Business: Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery.

IPO Date: 10-Oct-2006

Chairman & CEO: Mr. Christopher A. Bunka

Pres & Director: Mr. John M. Docherty M.Sc.

Listing: NASDAQ: LEXX

Country: Canada

Headquarters: Kelowna, BC

Website: https://www.lexariabioscience.com

Market cap: $16.42 Mln

Revenue (TTM): $0.28 Mln

Earnings (TTM): $-7.15 Mln

Cash: $8.91 Mln

Total Debt: $0.00 Mln

Insider's Holding: 17.81%

Liquidity: Low

52 Week range: $1.86 - 12.50

Shares outstanding: 5,951,000

10 Years Aggregate:

• CFO: $-15.43 Mln
• EBITDA: $-18.81 Mln
• Net Profit: $-24.11 Mln